For example, Russo et al. (2019) described in CRC models that treatments with cetuximab (moAb anti-EGFR) or dabrafenib (BRAF inhibitor) increase ROS production, down-regulate DNA-repair pathways and up-regulate low-fidelity polymerases. The gene discussed is EGFR; the disease is colorectal carcinoma.